Summit Therapeutics Bests Merck's Top Selling Drug In Phase III Trial
Summit Therapeutics' ivonescimab poised for FDA approval, with the potential to disrupt the oncology market. Read more on ...
BioNTech raised to buy at Jefferies on new cancer drug
BioNTech (BNTX) stock traded higher on Tuesday after Jefferies upgraded the COVID-19 vaccine maker to Buy, citing the ...
BioNTech SE: A Strong Buy on BNT327’s Promising Cancer Treatment Prospects and Financial Fortitude
In a report released yesterday, John Newman from Canaccord Genuity maintained a Buy rating on BioNTech SE (BNTX – Research Report), with ...
The Pharma Letter3d
ESMO 2024: Encouraging mid-stage results on BioNTech asset
PM8002/BNT327 is a bispecific antibody targeting PD-L1 and VEGF-A. BioNTech agreed to pay up to $1 billion to develop the drug in an agreement with Biotheus signed in November last year. Results have ...
Buy Rating Reiterated for BioNTech SE on Promising Oncology Pipeline and BNT327’s Potential
In a report released today, Tazeen Ahmad from Bank of America Securities reiterated a Buy rating on BioNTech SE (BNTX – Research Report), ...